The cGAS-STING pathway is essential in inflammation-driven tumor occurrence and progression.[13] The chronic activation of downstream effector programs of cGAS-STING is associated with persistent inflammation and tumor progression.[13,14] In addition, the cGAS-STING pathway is also involved in the DNA sensing, immune infiltration, and anti-tumoral immune response.[14,15] The STING-targeted therapies have been considered a new class of anti-tumor immunotherapy candidates, and their safety and efficacy have been explored in multiple clinical trials (NCT02675439, NCT03010176, and NCT04144140). Here, STING1 is linked to neoplasm.